Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 06 May 2014 | By Alexander Gaffney, RAC,
Watch a drug advertisement in the US-any one, really-and one thing you're unlikely to hear any mention of is the drug's cost.
That's not always an accident, as the myriad of insurance companies, co-pays, state insurance programs, private assistance programs, coupons and other incentives mean that the true cost of a drug is rarely seen by consumers and is rarely the same for two people.
But assume, for a moment, that such an instance existed-that a drug ("Drug A") cost the exact same amount to every consumer, and that it offered no coupons, discounts, or any other incentives.
Now assume that the drug has a competitor, a drug ("Drug B") approved for the same condition and which costs twice as much despite possessing a safety and efficacy profile that is almost identical to Drug A.
Could Drug A advertise itself as having a cost advantage relative to Drug B?
The question is the subject of a new Federal Registerannouncement issued by the US Food and Drug Administration (FDA), which says it wants to answer a few nagging questions about how cost data makes its way into direct-to-consumer advertising.
"Currently, when price comparisons are made, the ad should also include context that the two drugs may not be comparable in terms of efficacy and safety and that the acquisition costs presented do not necessarily reflect the actual prices paid by consumers, pharmacies, or third party payers," FDA explains in the notice.
Despite that requirement, FDA says it's not convinced that consumers are necessarily paying attention to those disclaimers, and that the price comparison may imply that the products are interchangeable.
To see if this is this case, FDA's Office of Prescription Drug Promotion (OPDP) says it plans to "investigate, through empirical research, the impact of price comparison information and additional contextual information on prescription drug product descriptions."
The research will focus on DTC advertising aimed at diabetes patients (and physicians who treat diabetes) estimated to represent the "average" consumer (i.e. not healthcare or marketing professionals).
The proposed studies of 400, 1,000 and 2,940 participants (respectively) will compare DTC advertising using the following study design:
FDA says it hopes the proposed study will take about 30 minutes on average to complete for each participant.
Federal Register Notice
Tags: Cost Comparison, Drug Cost, Drug Pricing, DTC Advertising, Latest News, marketing, advertising
Regulatory Focus newsletters
All the biggest regulatory news and happenings.